The Journal of
Clinical Psychiatry

Suicide

Academic Highlights September 15, 2003

Reducing the Risk for Suicide in Schizophrenia and Affective Disorders.

J Clin Psychiatry 2003;64(9):1122-1129

Article Abstract

Reducing the Risk for Suicide in Schizophrenia and Affective Disorders. [CME]

Buy PDF for $40.00

Please sign in or purchase this PDF for $40.00.

Save

Cite

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Vol 85 • 2024 • Number 4

Read the Current Issue

Meta-Analysis

Changes in Cognition in Patients With Schizophrenia

Systematic Review

Diagnostic Assessment via Telehealth vs Face-to-Face

Original Research

Prevalence, Correlates, and Burden of Subthreshold PTSD in US Veterans

Original Research

Bridge Symptoms Between Borderline Personality and PTSD

Original Research

Gepirone-ER and Sexual Function in Patients with MDD

Original Research

Medication Use and Lines of Treatment in Patients With Insomnia Disorder

View current Issue